Phase II trial of piroxantrone in metastatic breast cancer
A Southwest Oncology Group study
Phase III Studies
- 25 Downloads
- 2 Citations
Summary
Thirty-two eligible patients with advanced metastatic breast cancer who had received no more than 1 prior chemotherapy regimen for metastatic disease (16 had received prior doxorubicin) were treated with piroxantrone at a dose of 120 mg/m2 intravenously every 21 days. In the twenty-seven patients evaluable for response, two partial responses were seen. Toxicities observed were primarily hematologic with grade 3 or greater granulocytopenia occurring in 34% of the patients. One patient developed symptomatic congestive heart failure at a total cumulative dose of 960 mg/m2. We conclude that piroxantrone given at this dose and schedule has minimal activity in patients with metastatic breast cancer.
Key words
piroxantrone oxantrazole anthrapyrazoles NSC-349174 Dup 942 breast cancerPreview
Unable to display preview. Download preview PDF.
References
- 1.Boring CC, Squires TS, Tong T, Montgomery S: Cancer statistics, 1994. Ca: a Cancer Journal for Clinicians 44(1):7–26, 1994Google Scholar
- 2.Friedman MA: New directions for breast cancer therapeutic research. Hematology — Oncology Clinics of North America 8(1):113–119, 1994Google Scholar
- 3.Showalter H, Johnson J, Werbel L, Leopold W, Jackson RC, Elslager E: 5-[(aminoakyl) amino] substituted antra [1,9-cd] pyrazol-6(2H)-ones as novel anticancer agents, synthesis and biological evaluations. J Med Chem 27:253–255, 1984Google Scholar
- 4.Leopold WR, Nelson JM, Plowman J, Jackson RC: Anthrapyrazoles, a new class of intercalating agents against murine tumors. Cancer Res 45:5532–5539, 1985Google Scholar
- 5.Burchenal J, Pancoast T, Elslayer E: Anthrapyrazole and amsacrine analogues in mouse and human leukemiain vitro andin vivo (abstract). Proc Annu Meet Am Assoc Cancer Res 26:339, 1985Google Scholar
- 6.Hantel A, Donehower RC, Rowinsky EK, Vance E, Clarke BV, McGuire WP, Ettinger DS, Noe DA, Grochow LB: Phase I study and pharmacodynamics of Piroxantrone (NSC 349174), a new anthrapyrazole. Cancer Res 50:3284–3288, 1990Google Scholar
- 7.Ames MM, Loprinzi CL, Collins JM, van Haelst-Pisani C, Richardson RL, Rubin J, Moertel CG: Phase I and clinical pharmacological evaluation of Piroxantrone hydrochloride (Oxantrazole). Cancer Res 50:3905–3909, 1990Google Scholar
- 8.Savarese DM, Denicoff AM, Berg SL, Hillig M, Baker SP, O'Shaughnessy JA, Chow C, Otterson GA, Balis FM, Poplack DG: Phase I study of high-dose Piroxantrone with granulocyte colony-stimulating factor. J Clin Oncol 9:1795–1803, 1993Google Scholar
- 9.Chang AY, Kim K, Glick J, Anderson T, Karp D, Johnson D: Phase II study of taxol, merbarone, and Piroxantrone in stage IV non-small cell lung cancer: The Eastern Cooperative Oncology Group Results. J Natl Cancer Inst 85:388–394, 1993Google Scholar
- 10.Williamson SK, Crowley JJ, Livingston R, Hantel A, Doroshow JH: Phase II trial of Piroxantrone in advanced non-small cell carcinoma of the lung: A Southwest Oncology Group Study. Invest New Drugs 10:29–30, 1992Google Scholar
- 11.Allen A, Wolf M, Crawford ED, Davis MP, Natale RB, Barnett ML: Phase II evaluation of Piroxantrone in renal cell carcinoma. A Southwest Oncology Group Study. Invest New Drugs 10:129–132, 1992Google Scholar
- 12.Jenkins TR, Tangen C, MacDonald JS, Weiss G, Chadman R, Hantel A: A Phase II trial of Piroxantrone in adenocarcinoma of the pancreas: A Southwest Oncology Group Study. Invest New Drugs 11:329–331, 1993Google Scholar
- 13.Ingle JN, Kuross JA, Maillard JA, Loprinzi CL, Jung SH: Evaluation of piroxantrone in women with metastatic breast cancer and failure on non-anthracycline related chemotherapy: A North Central Cancer Treatment Group Trial. Proc Annu Meet Am Soc Clin Oncol 12:A140, 1993Google Scholar
Copyright information
© Kluwer Academic Publishers 1994